All In Biotech

Drug Trial Radar · NCT06372496

Pragmatic Open - Label Randomized Clinical Trial of FF/UMEC/VI vs Non-ellipta Usual Care ICS-LABA for Adult Participants With Uncontrolled Asthma

A Phase 4, 52-week (Primary Analysis at 24-weeks), Randomized, Stratified, Open-label, Active-controlled, Parallel-group, Effectiveness Study, Comparing FF/UMEC/VI With Non-ellipta Usual Care (ICS/LABA) in Adult Participants With Uncontrolled Asthma

Last checked: Nov 19, 2026Latest source record: Oct 6, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingResults posted on the registryPivotal-lookingRandomized with 1,358 participants. This is a heuristic, not a regulatory label.

Status

Active, not recruiting

Enrollment

1,358

Actual

Start

Apr 16, 2024

Primary completion

Jul 28, 2025

Study completion Jun 14, 2027

Sponsor

Lead sponsor
GlaxoSmithKlineGSK (GSK)
Sponsor type
Industry
First posted
Apr 18, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The goal of this study is to assess and compare the effectiveness of fluticasone furoate/umeclidinium bromide/vilanterol trifenatate (FF/UMEC/VI) with inhaled corticosteroids/long-acting beta-2 agonists (ICS/LABA) in adult participants with uncontrolled asthma

Conditions

  • Asthma

Interventions

  • Fluticasone furoate/umeclidinium bromide/vilanterol trifenatateDrug

    Participants will receive FF/UMEC/VI

  • Inhaled corticosteroids/long-acting beta-2 agonistsDrug

    Participants will receive ICS/LABA

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change From Baseline (CFB) in Trough Forced Expiratory Volume in 1 Second (FEV1) at Week 24Time frame: Baseline (Day 1) and at Week 24

Locations

117 sites in 8 countries. Site status is shown where the registry gives one.

  • GSK Investigational Site

    Centreville, Alabama

  • GSK Investigational Site

    Little Rock, Arkansas

  • GSK Investigational Site

    Newport Beach, California

  • GSK Investigational Site

    Newark, Delaware

  • GSK Investigational Site

    Clearwater, Florida

  • GSK Investigational Site

    Miami, Florida

  • GSK Investigational Site

    Miami, Florida

  • GSK Investigational Site

    Miami, Florida

  • GSK Investigational Site

    North Miami Beach, Florida

  • GSK Investigational Site

    Orlando, Florida

  • GSK Investigational Site

    Palm Springs, Florida

  • GSK Investigational Site

    Port Charlotte, Florida

  • GSK Investigational Site

    Tallahassee, Florida

  • GSK Investigational Site

    Normal, Illinois

  • GSK Investigational Site

    New Orleans, Louisiana

  • GSK Investigational Site

    Bangor, Maine

  • GSK Investigational Site

    Detroit, Michigan

  • GSK Investigational Site

    Warren, Michigan

  • GSK Investigational Site

    Missoula, Montana

  • GSK Investigational Site

    Papillion, Nebraska

  • GSK Investigational Site

    Brick, New Jersey

  • GSK Investigational Site

    Linwood, New Jersey

  • GSK Investigational Site

    New Windsor, New York

  • GSK Investigational Site

    Asheville, North Carolina

  • GSK Investigational Site

    Charlotte, North Carolina

  • GSK Investigational Site

    Greenville, North Carolina

  • GSK Investigational Site

    Winston-Salem, North Carolina

  • GSK Investigational Site

    Cincinnati, Ohio

  • GSK Investigational Site

    DuBois, Pennsylvania

  • GSK Investigational Site

    Philadelphia, Pennsylvania

  • GSK Investigational Site

    Pittsburgh, Pennsylvania

  • GSK Investigational Site

    Rock Hill, South Carolina

  • GSK Investigational Site

    Spartanburg, South Carolina

  • GSK Investigational Site

    Beaumont, Texas

  • GSK Investigational Site

    Dallas, Texas

  • GSK Investigational Site

    Bellingham, Washington

  • GSK Investigational Site

    Buenos Aires, Argentina

  • GSK Investigational Site

    Buenos Aires, Argentina

  • GSK Investigational Site

    Buenos Aires, Argentina

  • GSK Investigational Site

    Buenos Aires, Argentina

Showing 40 of 117 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.